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Abstract To describe factors associated with early treat-
ment of migraine, and to examine reasons patients do not
treat early, this cross-sectional observational study email-
recruited migraineurs C18-years-old who were currently
prescribed acute migraine medication. Within 24 h of
migraine resolution, eligible patients completed an online
migraine strikes questionnaire which addressed pain severity,
associated symptoms, and other variables including reasons
for not treating early. Results reported were descriptive.
Among 1,044 evaluable patients, early treatment was sig-
nificantly associated with several factors such as leisure
activity at onset (OR 1.32, P = 0.010), photophobia (OR
1.39, P = 0.013), diagnosis of migraine with aura (OR 1.36,
P = 0.004), and other factors. Among 840 patients who
reported wanting to treat earlier desire to reserve medication
for a severe migraine was the most common reason given
for not doing so (51.2%). Overcoming these factors may
facilitate earlier migraine treatment.
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Migraine is a disabling disorder which affects about 30 million
people in the United States [1]. Much research has been reported
on the risk factors, triggers, premonitory symptoms, and con-
comitant symptoms associated with migraine attacks, such as
nausea, photophobia, and visual disturbances [2–7]. Clinical and
observational data from patients taking triptans have consis-
tently demonstrated the benefits of treating early (i.e., at the onset
of pain) [8–13], but despite this evidence, 69% of migraineurs
report that they would not treat their migraine pain as soon as
they feel pain [14]. In addition to issues regarding efficacy and
potential side effects of triptans, other factors may affect
patients’ ability or willingness to treat early. This study inves-
tigated other such external environmental factors which may
influence patients’ decision to treat early, and factors which may
prevent patients from treating a migraine as early as they desire.
Methods
Study design
This cross-sectional observational survey study [migraine
strikes study (MIST)] was conducted from November to
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December 2006. A central Institutional Review Board
(IRB) (ESSEX IRB, Lebanon, NJ) approved the study
protocol, survey instrument, and the statement of informed
consent. Consumer Health Sciences International (CHS), a
contract research organization, provided each patient with
full and adequate information about the objective and
procedures of the study. Compensation was provided by
the Lightspeed Consumer Panel to participants in the form
of ceremonial ‘‘points,’’ which patients were eligible to
redeem at the panel’s website for various retail products
such as online gift certificates, music downloads, and
kitchen appliances.
Patients and procedures
To be eligible for the study, patients had to be at least 18-
years-old and fluent in English. Patients had to have been
diagnosed with migraine (with or without aura) by a phy-
sician, and had to have a current prescription for acute
migraine medication(s). Patients were contacted via the
internet to participate in the study. In an initial invitation
email circular, patients were informed about the purpose
and design of the study. If patients experienced a migraine
attack within 7 days after they received the invitation
email, they were invited to report their migraine experience
within 24 h of its resolution. Patients accessed a password-
protected web link attached in the initial email circular.
Those who gave consent to participate were allowed to
proceed to the migraine strikes questionnaire (Electronic
supplementary Appendix 1).
In the migraine strikes questionnaire, participants
reported circumstances of the migraine attack that occurred
within the past 24 h, such as the time and location in which
the migraine occurred, and details about any therapy the
patient used to treat the migraine. Information about
migraine and other headache history was also collected.
Consumer Health Sciences International fielded the study
by setting up data programming for the migraine strikes
questionnaire, tracking and monitoring patient’s compli-
ance with completing the questionnaire, and sending email
reminders and thank you notes to participants. Consumer
Health Sciences International collected the data, which
was accessible only to research team members. Upon
stripping the data of all patient-identifying information,
CHS provided the sponsor (Merck and Co., Inc.) with a
cumulative data base in SAS format, which contained all
information on headache experience for the migraine
strikes questionnaire.
Statistical methods
To assess the factors associated with early treatment pat-
terns, questions evaluated included pain severity and
associated symptoms, activities at onset of migraine, tim-
ing and selection of medication, physician-level variables,
and co-morbid headache diagnoses. Logistic regression
was used to identify factors associated with early treat-
ment; adjustments were made for covariates. Chi-square
and Student’s t tests were used for univariate analysis,
where appropriate, and a binary logistic regression model
using backward elimination was used for multivariate
analyses. The dependent variable was ‘‘Treat early’’
(defined as treating within 1 h of headache onset), and
candidate independent variables were those determined to
be clinically relevant and/or which had a trend toward
significance (P \ 0.1) on univariate analysis.
To assess reasons for not treating early even when
desiring to do so, data were collected for questions about
whether the attack was treated when desired (‘‘Did you
want to take your medication earlier than you actually
did?’’), factors that may have prevented earlier treatment
(‘‘What prevented you from taking the medication
sooner?’’), physician specialty (‘‘Are you currently seeing
any of the following physicians for your headaches?’’),
physician education regarding early treatment (‘‘Has your
physician ever instructed or advised you to take your
migraine medications ‘early’ when the pain is still
‘mild’?’’) and satisfaction with pain relief (‘‘How satisfied
were you with the pain relief you achieved with the med-
ication you took for this migraine attack?’’).
Descriptive statistics were used to examine factors
potentially hindering earlier treatment and Chi-square tests
were used to examine univariate associations.
Results
Early treatment
Table 1 shows patient demographics and baseline charac-
teristics. Of the 2,001 migraineurs who participated (mean
age 42.7, 74.2% female), 1,856 (92.8%) reported at least
one associated symptom (nausea, vomiting, photophobia,
or phonophobia) at headache onset during their attack,
providing supporting evidence that participants were
correct in their ascertainment of migraine. Of the 1,752
participants who provided information on treatment timing,
1,044 treated their migraine early (i.e., within 1 h of
headache onset) (59.6%).
Univariate analysis (Table 2) showed that factors sig-
nificantly positively associated with treating early
included increasing age, male gender, doing something for
fun/leisure at onset, presence of photophobia, diagnosis of
migraine with aura, physician advice about early treat-
ment, and regular adherence to physician’s instructions.
Patients were significantly less likely to treat early if they
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were at work or school at the time of migraine onset, or if
they had co-morbid tension-type and/or chronic daily
headache.
Table 1 Patient demographics and baseline characteristics
Baseline characteristics N = 2,001







At least one of the above 92.8





Age at first migraine, years (SD) 23.2 (11.3)
















Student or unemployed 39.4
Education level (%)
High school or less 17.5
Some college 38.8
College or graduate degree 43.7






Chronic daily ([15/month) 33.6
Sinus 66.6
SD standard deviation
Table 2 Univariate analysis: early treatment
Demographic characteristics Treat early (%)
N = 1,752
Age
\30, n = 293 52.9
30–39, n = 469 56.3
40–49, n = 515 59.8
50–59, n = 339 64.3
C60, n = 136 72.8
P-value \0.001
Gender
Female, n = 1,291 58.0
Male, n = 461 64.0
P-value 0.025
Employment status
Full-time, n = 847 60.1
Part-time, n = 216 55.1
Student or unemployed, n = 689 60.4
P-value 0.353
Education level
High school degree or less, n = 305 57.1
Some college, n = 681 59.5
College graduate, n = 766 60.7
P-value 0.544
Prescription drug insurance
Yes, n = 1,551 60.2
No, n = 201 54.7
P-value 0.135
When your migraine began, were you…?
At work or school?
Yes, n = 248 52.0
No, n = 1,504 60.8
P-value 0.009
Doing something for fun or leisure?
Yes, n = 676 63.3
No, n = 1,076 57.3
P-value 0.012
In a private place?
Yes, n = 1,256 60.4
No, n = 496 57.7
P-value 0.302
A critical member of the task at hand?
Yes, n = 779 58.3
No, n = 973 60.6
P-value 0.318
Doing something as part of your daily routine?
Yes, n = 1,316 59.6
No, n = 436 59.6
P-value 0.963
Associated symptoms
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After adjusting for age, gender, and pain severity, multi-
variate analysis showed that early treatment was significantly
positively associated with leisure activity at onset [odds ratio
(OR) 1.32, P = 0.010], photophobia (OR 1.39, P = 0.013),
diagnosis of migraine with aura (OR 1.36, P = 0.004),
prior early treatment instruction by a physician (OR 1.75,
P \ 0.001), regular adherence to physicians’ instructions
(OR 2.31, P \ 0.001). Early treatment was significantly
negatively associated with co-morbid tension and/or chronic
daily headaches (OR 0.68, P = 0.004 and OR 0.78,
P = 0.022, respectively) (Table 3). Being at work or school
at onset did not retain a significant association with early
treatment in the multivariate analysis.
Reasons for not treating earlier
Of the 2,001 migraineurs who completed the survey, 840
(42.0%) reported willingness to treat their migraine ear-
lier. Among the 764 patients who wanted to treat earlier
and who also provided information on treatment timing,
379 (49.6%) treated within 1 h of headache onset, com-
pared with 67.3% of patients who did not want to treat
Table 2 continued
Demographic characteristics Treat early (%)
Nausea
Yes, n = 1,042 60.4
No, n = 710 58.5
P-value 0.423
Vomiting
Yes, n = 212 57.6
No, n = 1,540 59.9
P-value 0.518
Photophobia
Yes, n = 1,428 61.1
No, n = 324 53.1
P-value 0.008
Phonophobia
Yes, n = 1,364 60.1




Triptan, n = 1,091 60.1
Non-triptan prescription, n = 440 60.2




With aura, n = 781 63.8
Without aura, n = 971 56.2
P-value 0.001
Migraines per month
B2, n = 593 59.4
3–4, n = 439 59.7
5–8, n = 352 61.7
C9, n = 368 52.9
P-value 0.782
General migraine severity
Mild, n = 40 60.0
Moderate, n = 714 59.8
Severe, n = 464 59.4
P-value 0.986
Presence of prodromal symptoms
Yes, n = 942 58.6
No, n = 717 61.5




Yes, n = 1,384 57.7
No, n = 368 66.9
P-value 0.001
Table 2 continued
Demographic characteristics Treat early (%)
Cluster
Yes, n = 646 60.4
No, n = 1,106 59.1
P-value 0.610
Chronic daily ([15/month)
Yes, n = 583 54.6
No, n = 1,169 62.1
P-value 0.002
Sinus
Yes, n = 1,153 58.5




Primary care, n = 1,260 750 (59.5)
Specialist, n = 403 245 (60.8)
Others, n = 89 49 (55.1)
P-value 0.605
Physician advisement regarding treat early
Yes, n = 1,447 889 (61.4)
No, n = 305 155 (50.8)
P-value \0.001
Regular adherence to physician’s instructions
Rarely/sometimes, n = 343 146 (42.6)
Most of the time/always, n = 1,361 871 (64.0)
P-value \0.001
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earlier (P \ 0.001). Of those who desired earlier treat-
ment, the median time to treatment was 60 min,
compared with 20 min among patients who did not want
to treat earlier (P \ 0.001) (Fig. 1). The most commonly
stated reason for not treating when wanted was the desire
to reserve medication for a severe migraine (51.2%).
Other reasons included not having medication on hand
(34.9%), health plan quantity limit on drugs (27.0%),
inability to swallow because of nausea (18.7%), not
having access to fluid (17.3%), and not having privacy
(13.5%) (Fig. 2).
Desire to treat earlier was not significantly associated
with physician education regarding early treatment; 82.1%
among those desiring to treat early reported having been
educated about early treatment by their physician versus
80.3% among those who did not want to treat earlier
(P = 0.293). Likewise, between-group differences were
not significant based on physician specialty (71.4 vs. 70.8%
seeing a primary care physician, P = 0.760; 22.7 vs.
22.1% seeing a headache specialist, P = 0.750; and 5.8 vs.
7.1% seeing other or no physician, P = 0.273). Desire to
treat earlier was associated with dissatisfaction with pain
relief (18.6 vs. 14.3%, P = 0.015).
Discussion
Early treatment of migraine has been shown to be partic-
ularly beneficial compared with treating[1 h after onset of
pain, but it is known that not all patients take advantage of
this benefit. To elucidate the possible reasons, which might
then indicate paths forward in terms of helping patients
maximize the benefit of migraine treatment, data from this
questionnaire were assessed to answer two main questions
about early treatment among a sample population of mi-
graineurs. First, the analysis assessed what proportion of
patients treated their headache within 1 h of onset; second,
among those who did not treat their migraine as early as
they wanted to, the data were evaluated to help determine
why not. Within 24 h of resolution of a headache, patients
reported the circumstances of the migraine attack, includ-
ing their physical location and time when the migraine
occurred, their activities at migraine onset, and medication
use. Patients also provided information on their personal
migraine history and its treatment, presence of migraine-
associated symptoms, and current headache frequency and
severity.
The analysis found that more than half (approximately
60%) of patients treated their headache within an hour of
its onset; thus, about 40% of patients waited more than an
hour after the onset of pain to take therapy for the migraine.
These results are in accord with those of Gallagher et al.
[15], who also reported that prescription medications were
delayed in 40% of migraine episodes, and Foley et al. [14],






Age (continuous) 1.02 1.01–1.03 \0.001
Female 0.81 0.64–1.02 0.071
Pain severity at onset (none,
mild, moderate, severe)
0.89 0.77–1.02 0.096
Leisure activity at onset 1.32 1.07–1.62 0.010
Photophobia 1.39 1.07–1.81 0.013
Migraine with aura (vs. all others) 1.36 1.10–1.67 0.004
Tension headaches 0.68 0.53–0.89 0.004
Chronic daily headaches 0.78 0.63–0.96 0.022
Physician early treatment instruction 1.75 1.33–2.30 \0.001
Regular adherence to
physician’s instructions




Did not want to treat
earlier (n=988)
Wanted to treat earlier
(n=764)
Time from Headache Onset to Medication Therapy
Median=60 min* 
Median=20 min*
0 20 40 60 80 100 120 140 160 180
Time (minutes)
Fig. 1 Time from headache onset to first dose of medication.*
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No privacy
No access to fluid
Could not swallow
because of nausea
Health plan quantity limit





Fig. 2 Factors preventing early treatment among those who sought it
(n = 840)
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who reported that migraine medications were delayed by
49% of patients. These findings clearly indicate a need to
address potential reasons for delays in treatment, in order
to ensure that as many patients as possible are able to
optimize their use of treatment.
To obviate unwanted delays, it is useful to understand
specific reasons that patients, who may indeed know that
early treatment is beneficial, nevertheless may not be tak-
ing their medication as early as possible. About 42% of
patients indicated that they wanted to treat their migraine
earlier than they actually did. Of those who expressed
desire for earlier treatment, only about half treated their
most recent migraine within an hour. The desire to reserve
medication for a severe migraine was the most common
reason given for delaying treatment, reported in fully half
the patients who wanted to treat earlier. The next most
common reason, reported in one-third of patients, was not
having the medication on hand, and about one quarter of
the patients said that their health plan quantity limit on
drugs prevented them from treating as early as they wan-
ted; additional reasons included nausea interfering with the
ability to swallow, lack of access to fluid, and lack of
privacy.
These results are in general agreement with the small
amount of prior work that has previously been done in this
area. In the aforementioned survey by Gallagher et al. [15],
the authors reported that the most common reasons for
delaying prescription medication use were medication
access issues, limited numbers of pills, difficulties in
functioning, and concerns about adverse events. Interest-
ingly, Gallagher did not report on what we found to be the
most commonly reported reason for delay: the desire to
reserve medications for severe migraine. This commonly
cited reason for treatment delay was also observed by
Foley et al. [14]. Of patients who reported delayed treat-
ment, 70% cited wanting to wait and see if the attack was
really a migraine attack as a reason for the delay, and 46%
cited wanting to take medication only for a severe attack.
Despite the observed high rate of reported migraine-
associated symptoms at headache onset, we observed that
patients with other co-morbid primary headaches were
more likely to delay treatment. Epidemiologic research has
shown that up to 90% of migraine patients also suffer from
tension-type headache [16] and migraine and tension-type
headaches share many important similarities [17]. To
optimize migraine care, physicians should routinely educate
their patients about early migraine symptoms, particularly
for patients recently diagnosed with migraine, in addition to
prescribing appropriate medications. Both Gallagher and
Foley also found concern about medication side effects as a
factor in treatment delay, reported by 15 and 37%, respec-
tively. Our study did not directly explore fear of side effects
as a potential reason for delaying treatment.
Some of the stated reasons for treatment delay can be
addressed with practical adjustments, such as carrying
medication when leaving home. Alternative formulations
(e.g., rapidly dissolving tablet, nasal spray) can be con-
sidered in patients prone to migraine-associated nausea or
who are frequently on the go and may not have continuous
access to water or other liquids. However, solutions to the
most commonly reported obstacles are not straightforward.
For example, in patients with other types of headaches and/
or chronic daily headache, the advantages and disadvan-
tages of early treatment must be carefully weighed, bearing
in mind that frequent use of certain acute migraine medi-
cations may predispose to medication overuse headache
and chronic migraine [18].
Several factors act as limitations on the analysis of
reasons for delayed treatment. It is possible that the ret-
rospective desire to treat earlier may be influenced by
severity of headache pain and/or any associated symptoms
the patient may have experienced. Thus, the wish itself to
treat earlier may not have emerged until after the first hour
of migraine. Moreover, the survey does not account for the
fact that reasons for not treating may vary by attack, within
the same patient. For example, on two different occasions
in which a migraine begins, a patient may have consider-
ably easier access to medication in one situation versus the
other. In addition, other practical considerations that could
interfere with timely treatment may not have been captured
by this survey.
In summary, a large proportion of migraine patients did
not treat their headache within the first hour of headache
onset. The study found that the most common reasons for
the delay in treatment were (1) a wish to reserve the
medication for a severe migraine, and (2) lack of easy
access to the medication. Finding ways to overcome these
and other practical obstacles preventing patients from
medicating early may help a greater number of patients to
relieve their migraines faster.
Acknowledgments Merck and Co., Inc. funded the study. Drs.
Golden and Hu are employees of Merck and Co., Inc. who may
potentially own stock and/or hold stock options in the company. Dr.
Evans was an employee of Merck during the conduct of this study and
the writing of this manuscript.
Conflict of interest Drs. Golden and Hu are employees of Merck
and Co., Inc., and may own stock or stock options in the company. Dr.
Evans was an employee of Merck during the conduct of this trial and
the writing of this manuscript, and may own stock in the company.
References
1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M
(2001) Prevalence and burden of migraine in the United States:
data from the American Migraine Study II. Headache 41:646–
657
98 J Headache Pain (2009) 10:93–99
123
2. Kelman L (2005) Validation of the classification of migraine with
aura (IHS A1.1) proposed in ICHD-2. Headache 45:1339–1344
3. Martin VT, Penzien DB, Houle TT, Andrew ME, Lofland KR
(2005) The predictive value of abbreviated migraine diagnostic
criteria. Headache 45:1102–1112
4. Mulleners WM, Aurora SK, Chronicle EP, Stewart R, Gopal S,
Koehler PJ (2001) Self-reported photophobic symptoms in
migraineurs and controls are reliable and predict diagnostic
category accurately. Headache 41:31–39
5. Silberstein SD (1995) Migraine symptoms: results of a survey of
self-reported migraineurs. Headache 35:387–396
6. Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF,
Olesen J et al (2003) Premonitory symptoms in migraine. An
electronic diary study. Neurology 60:935–940
7. Kelman L (2004) The premonitory symptoms (prodrome): a
tertiary care study of 893 migraineurs. Headache 44:865–872
8. Mannix L (2008) A review of the 5HT1B/1D agonist rizatriptan:
update on recent research and implications for the future. Expert
Opin Pharmacother 9:1001–1011
9. Ng-Mak DS, Hu XH, Chen Y, Ma L, Solomon G (2007) Times to
pain relief and pain freedom with rizatriptan 10 mg and other oral
triptans. Int J Clin Pract 61:1091–1111
10. Moschiano F, D’Amico D, Allais G, Rigamonti A, Melzi P,
Schieroni F et al (2005) Early triptan intervention in migraine: an
overview. Neurol Sci 26(Suppl 2):s108–s110
11. Hu XH, Raskin NH, Cowan R, Markson LE, Berger ML, On
behalf of The United States Migraine Study Protocol (USMAP)
Group (2002) Treatment of migraine with rizatriptan: when to
take the medication. Headache 42:16–20
12. Cady RK, Sheftell F, Lipton RB, O’Quinn S, Jones M, Putnam
DG et al (2000) Effect of early intervention with sumatriptan on
migraine pain: retrospective analyses of data from three clinical
trials. Clin Ther 22:1035–1048
13. Cady R, Martin V, Mauskop A, Rodgers A, Hustad CM, Ramsey
KE et al (2006) Efficacy of rizatriptan 10 mg administered early
in a migraine attack. Headache 46:914–924
14. Foley KA, Cady R, Martin V, Adelman J, Diamond M, Bell CF
et al (2005) Treating early versus treating mild: timing of
migraine prescription medications among patients with diagnosed
migraine. Headache 45:538–545
15. Gallagher RM, Kunkel R (2003) Migraine medication attributes
important for patient compliance: concerns about side effects
may delay treatment. Headache 43:36–43
16. Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R (2005) Has
the prevalence of migraine and tension-type headache changed
over a 12-year period? A Danish population survey. Eur J Epi-
demiol 20:243–249
17. Cady R, Schreiber C, Farmer K, Sheftell F (2002) Primary
headaches: a convergence hypothesis. Headache 42:204–216
18. Dodick D, Freitag F (2006) Evidence-based understanding of
medication-overuse headache: clinical implications. Headache
46(Suppl 4):S202–S211
J Headache Pain (2009) 10:93–99 99
123
